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Abstract
Background: Passively acquired maternal antibodies in infants may inhibit active immune responses to vaccines. Whether
maternal antibody against hepatitis B surface antigen (anti-HBs) in infants may influence the long-term immunogenicity of
hepatitis B vaccine remains unknown.
Methodology/Principal Findings: Totally 338 pairs of mothers and children were enrolled. All infants were routinely
vaccinated against hepatitis B based on 0-, 1- and 6-month schedule. We characterized the transplacental transfer of
maternal anti-HBs, and compared anti-HBs response in children of mothers with or without anti-HBs. In a prospective
observation, all 63 anti-HBs positive mothers transferred anti-HBs to their infants; 84.1% of the infants had higher anti-HBs
concentrations than their mothers. One and half years after vaccination with three doses of hepatitis B vaccine, the positive
rate and geometric mean concentration (GMC) of anti-HBs in 32 infants with maternal anti-HBs were comparable with those
in 32 infants without maternal antibody (90.6% vs 87.5%, P=0.688, and 74.5 vs 73.5 mIU/ml, P=0.742, respectively). In a
retrospective analysis, five and half years after vaccination with three doses vaccine, the positive rates of anti-HBs in 88
children of mothers with anti-HBs $1000 mIU/ml, 94 children of mothers with anti-HBs 10–999 mIU/ml, and 61 children of
mothers with anti-HBs ,10 mIU/ml were 72.7%, 69.2%, and 63.9% (P=0.521), respectively; anti-HBs GMC in these three
groups were 38.9, 43.9, and 31.7 mIU/ml (P=0.726), respectively.
Conclusions/Significance: The data demonstrate that maternal anti-HBs in infants, even at high concentrations, does not
inhibit the long-term immunogenicity of hepatitis B vaccine. Thus, current hepatitis B vaccination schedule for infants will
be still effective in the future when most infants are positive for maternal anti-HBs due to the massive vaccination against
hepatitis B.
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Introduction
Hepatitis B vaccine is highly effective in preventing hepatitis B
virus (HBV) infection. Antibodies directed against hepatitis B
surface antigen (anti-HBs) after vaccination with three doses
vaccine may maintain more than two decades in most vaccinees
[1,2]. As at December 2008, 177 countries included the hepatitis B
vaccine into their national infant immunization programs [3]; all
infants in these countries may be vaccinated with the vaccine.
Currently, around 30–40% of the child-bearing age women in
China are positive for anti-HBs as a result of vaccination or
natural infection [4]. Predictably, most child-bearing age women
worldwide will be positives in the future due to the mass
vaccinations. Accordingly, their infants will also be positive for
anti-HBs because of the transplacental transfer of maternal IgG.
Transplacentally acquired maternal antibodies protect infants
against infections in the early period of life. On the other hand,
maternal antibodies in infants may also interfere with the active
immune responses to vaccines against various pathogens, includ-
ing measles, poliovirus, hepatitis A virus, pertussis, tetanus and
diphtheria toxoids, and others [5–11]. Previously, we found that,
after the second dose vaccine, the antibody response to hepatitis B
vaccine in infants with maternal anti-HBs was lower than that in
infants without the maternal antibody, and the short-term
immunogenicity of hepatitis B vaccine in infants with high
maternal anti-HBs (.1000 mIU/ml) was significantly inhibited
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25130after vaccination with the third dose [12]. In this report, we
characterized the transplacental transfer of anti-HBs in infants and
measured the anti-HBs levels in children, who had been
vaccinated against hepatitis B in the presence or absence of
maternal anti-HBs during infantile period, to clarify whether the
long-term immunogenicity of hepatitis B vaccine is impaired by
the maternal anti-HBs.
Materials and Methods
Study subjects
The subjects recruited in this investigation included two groups
(Figure 1). One group was prospectively studied (Figure 1A). The
pregnant women (totally 820) attending the antenatal care unit at
Nanjing Drum Tower Hospital between December 2006 and
February 2007, were routinely screened for hepatitis B surface
antigen (HBsAg), anti-HBs, and antibody against hepatitis core
antigen (anti-HBc). Those who were positive for anti-HBs but
negative for HBsAg, or were negative for all the three markers
were explained the project and invited to participate. The women
with chronic diseases such as diabetes mellitus, asthma, HIV
infection, syphilis, and autoimmune diseases were excluded.
Finally, 63 anti-HBs positive mothers and their singleton newborn
infants were enrolled in analysis of anti-HBs placental transfer, and
the 63 infants were assigned into the group with maternal anti-
HBs. Concurrently, 52 women with negative for all the three
markers and without above chronic diseases consented to
participate and their infants were assigned into the group of
children without maternal anti-HBs.
Blood samples were collected from the women immediately
before or during delivery and from their newborns immediately
after birth by umbilical artery sampling. Of above infants, 32 were
followed with anti-HBs and other HBV serologic markers in April
2009. As controls, 32 infants of mothers without anti-HBs were
similarly followed. All infants were vaccinated with the same
vaccine lot (5 mg yeast recombinant HBsAg per dose) according to
the recommended schedule, i.e, three doses, within 24 hours, 1
month, and 6 months respectively after birth as previously
described [12]. The vaccine, which has been licensed by Merck
& Dohme Co, was manufactured by Shenzhen Kangtai Biological
Company, China.
Another group was retrospectively investigated (Figure 1B). In a
study on the provincial prevalence of birth defects conducted
August 2002 to July 2004 [13], serum samples from 19 904
pregnant women aged 20–42 years, at gestation of 15–20 weeks,
from 8 counties (rural area) and 6 cities (urban) in Jiangsu
Province, China, were collected and stored at 230uC. These
women had been selected to be the representatives of the pregnant
women population in Jiangsu and all delivered their infants in
hospitals. Recently, we retrospectively measured the HBV
serologic markers in the 6398 sera, which were randomly selected
from above samples, and found that 2357 (36.84%) of them were
positive for anti-HBs [4]. According to the anti-HBs status of
women during their pregnancy, we followed 328 pairs of mothers
and children and collected children’s blood samples during
October 2009 through March 2010. HBsAg was negative in all
328 children, in whom 48 were not vaccinated as the
recommended schedule, 36 received booster immunization, and
one experienced a natural infection because of the presence of
anti-HBc. Thus, we excluded these 85 children and finally
included 243 children in the observation, of whom 88, 94, and
61 were born to mothers with anti-HBs $1000, 10–999, and
,10 mIU/ml, respectively (Figure 1B). Among the 61 mothers
with anti-HBs ,10 mIU/ml, 24 were totally absence of anti-HBs,
and 13, 10, and 14 had the antibody ,2, 2.1–4.9, and 5–
9.9 mIU/ml, respectively. Because the mass vaccination in China
is administered by each Provincial Health Department, all the
hepatitis B vaccine used in this group children was from the same
manufacturer as used in the prospective group and had equal
amount of recombinant HBsAg (5 mg) in each dose.
This study was approved by the institutional review boards of
Nanjing Drum Tower Hospital and Jiangsu Family Planning
Institute. Written Informed consent was obtained from each
woman in the prospective cohort; the infant/child’s consent was
assigned by his/her mother. In the retrospective cohort, the
mothers consented to participate in the birth defect study
conducted from August 2002 to July 2004 [13] and their serum
samples were used in this study; the mothers consented to be
interviewed and consented to their children’s participation in the
following-up during October 2009 through March 2010. All
infants were also administered with other routine vaccinations as
recommended by China Expanded Program on Immunization.
Assays for HBV serologic markers
Qualitative tests of HBsAg, anti-HBs, and anti-HBc in serum
were performed with commercial enzyme immunoassay (EIA) kits
(Huakang Biotech, Shenzhen, China). The commercial micropar-
ticle enzyme immunoassays (AxSYM AUSAB, Abbott, North
Chicago) were used for quantitatively determining anti-HBs and
anti-HBc. All samples were tested by the two technicians who were
unaware of the serum identity. Paired maternal and neonatal sera
were analyzed in parallel. When anti-HBs level was beyond the
upper detection limit (1000 mIU/ml), the sera were retested by
dilution with 20% bovine fetal serum in phosphate-buffer saline
(PBS).
Analysis of anti-HBs IgG subclasses
Analysis of the IgG subclasses of anti-HBs was performed by an
EIA as previously reported [14,15] with minor modifications.
Anti-HBs positive sera were 5-fold diluted and added to microtiter
plate wells coated with recombinant HBsAg (Huakang Biotech).
After incubation and washes, mouse anti-human IgG subclass
specific monoclonal antibodies (0.1 mg/well in 100 ml), including
IgG1, IgG2, IgG3 (Invitrogen, Carlsbad, CA), and IgG4 (clone
HO6023, AbD Serotec, Oxford, UK) were used to probe the
subclasses of anti-HBs respectively. The activity of anti-HBs
specific for each of the four IgG subclasses was expressed as the
OD450 of samples.
HBsAg inhibition test
Binding of anti-HBs to HBsAg, a surrogate test for in vitro
neutralization, was performed as reported elsewhere [16,17] with
modifications. An HBsAg-positive serum from a hepatitis B patient
was titrated and 50-fold diluted in PBS based on the preliminary
experiment results. The 25 ml aliquot of the diluted serum was
mixed with equal volume of each of the paired maternal and
neonatal sera (including negative controls) at room temperature
for 1 h. The mixture was then subjected to detection of the HBsAg
with the EIA kit (Huakang Biotech), and the OD450 was read on
the ELISA reader. The inhibition was expressed by a percentage
calculated by the following formula: ([OD450 of negative
control2OD450 of anti-HBs positive sample]/OD450 of negative
control)6100.
Statistical analysis
Data were analyzed using SPSS version 13 (SPSS Inc., Chicago,
USA). Correlations between maternal and cord blood titers were
Maternal Anti-HBs and Hepatitis B Vaccine
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continuous variables were analyzed by t-test (comparison between
two groups) or one-way ANOVA test (comparison among three
groups) and a x
2 test was used to analyze and compare categorical
data. Anti-HBs $10 mIU/ml was defined to be positive. When
compared among different subgroups, the anti-HBs level was
expressed by geometric mean concentration (GMC) followed by
minimum and maximum values. When anti-HBs in a serum
was absolutely absent, the sample was considered to have
0.01 mIU/ml in calculating anti-HBs GMC. The Mann-Whitney
Figure 1. Flow diagram of study subjects. A, prospective cohort; B, retrospective cohort. HBsAg, hepatitis B surface antigen; a-HBs, antibody
against HBsAg; a-HBc, antibody against hepatitis B core antigen.
doi:10.1371/journal.pone.0025130.g001
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GMC between subgroups. A P value of ,0.05 was considered
statistically significant.
Results
Transplacental transfer of maternal anti-HBs
Transplacental transfer of maternal anti-HBs was analyzed in
63 pairs of anti-HBs positive mothers and their infants. The
mothers were 20–36 years of age (mean, 27.262.8). Of these
mothers, 41 had been vaccinated against hepatitis B, 21 had not
been vaccinated, and the remaining one was uncertain. All of the
21 unvaccinated women were positive for anti-HBc, indicating
that they acquired the specific immunity by resolved HBV
infection. All full-term infants were healthy (Apgar scores .8) at
birth with body weights 2800–4600 g (mean, 3354.76369.6). The
male and female infants were 28 and 35 respectively. Each of
the 63 mothers transferred the anti-HBs to her infant because
anti-HBs was positive in each cord serum. To analyze the trans-
placental transfer efficiency, we compared the anti-HBs concen-
trations between maternal and cord sera. As shown in Table 1,
84.1% of the cord serum samples had higher concentrations than
the corresponding maternal sera. Figure 2 shows the significant
positive correlation between maternal and cord blood anti-
HBs (linear regression analysis, y=1.393x237.286, r=0.992,
P,0.001). Infants’ sex, the delivery modes, and mothers’ ages
were not correlated with the efficiency of transplacental anti-HBs
transfer (data not shown).
IgG subclass profiles of anti-HBs
Since anti-HBs in most of the infants was higher than that in
their mothers (Table 1), and IgG1 is the most efficiently
transplacentally transported subclass [18], we attempted to clarify
which subclass of anti-HBs IgG was predominant in the infants.
We selected 20 paired mother-infant sera (11 vaccinated, 8 not
vaccinated, and 1 uncertainty of the vaccination) and analyzed the
anti-HBs IgG subclasses. Anti-HBs IgG1 subclass was predomi-
nant in all these samples, regardless of the antibody induced by
vaccination or by resolved HBV infection, and three other IgG
subclasses accounted for minor portion of the total anti-HBs.
Figure 3 shows the representative results of the four paired sera.
Binding of HBsAg by maternal anti-HBs
Since an efficient in vitro cell culture system is not available for
testing the neutralizing activity of anti-HBs, we used a surrogate
assay to test the inhibition of HBsAg by maternal anti-HBs in the
cord blood. Concurrently, the neutralization of HBsAg by the
mothers’ sera was also tested. We measured the inhibition of 21
paired mother-infant sera including those containing the highest
and lowest concentrations of anti-HBs in the samples. Figure 4
shows that all 21 undiluted paired sera inhibited the reactivity of
HBsAg, more than 95% by the sera containing high level anti-HBs
(paired samples 1–4) and nearly 20% by the sera having the low
titers. When the sera was 5-fold diluted, the inhibition also
decreased, except for the paired samples 1, in which 5-fold diluted
sera still had the antibody .1000 mIU/ml because of their high
levels of anti-HBs (6613 and 9663 mIU/ml in mother’s and cord’s
sera respectively); the data demonstrate the specificity of the assay.
Generally, the inhibition tended to be in a dose-dependent
manner although some samples containing relatively low concen-
trations had greater inhibition rates. Noticeably, the cords’ blood
usually had higher levels than mothers’ blood (Table 1 and
Figure 2); however, the inhibition rates of the paired sera were
comparable.
Anti-HBs levels in children vaccinated in the presence or
absence of maternal anti-HBs
To clarify whether maternal anti-HBs in infants may impair the
long-term immunogenicity of hepatitis B vaccine, we prospectively
measured anti-HBs in 32 children of mothers with positive anti-
HBs and in 32 children of mothers with negative anti-HBs around
one and half years after the infants had been vaccinated with three
doses vaccine. The general characteristics of mothers and their
infants were comparable in the two subgroups (Table 2). The
positive rates of anti-HBs were 90.6% and 87.5% respectively
(x
2=0.161, P=0.688), and the anti-HBs GMC levels were also
comparable (74.5 vs 73.5 mIU/ml, Mann-Whitney U test,
Z=20.282, P=0.742) (Table 2).
To investigate whether high titer of maternal anti-HBs in infants
may have long-term influence on the immune response to hepatitis
B vaccine, we further compared anti-HBs response in children
with different levels of maternal anti-HBs. Of the 32 infants of
anti-HBs positive mothers, 26 had maternal anti-HBs 31.5–
895.0 mIU/ml and 6 had the antibody 1001.0–9663.0 mIU/ml in
their cord blood. At approximately one and half years after the
three doses vaccine, the rates of positive anti-HBs in above
subgroups were 92.3% (24 of 26) and 83.3% (5 of 6) respectively
(P=0.525), and the anti-HBs GMT was comparable (74.2 vs
81.7 mIU/ml, P=0.562).
Figure 2. Correlation of transplacentally transferred anti-HBs
in infants with the maternal antibody (linear regression
analysis, y=1.393x237.286, r=0.992, P,0.001, n=63).
doi:10.1371/journal.pone.0025130.g002
Table 1. Comparison of anti-HBs between infants and
mothers.
Ratio of cord/maternal anti-HBs No. of paired sera (%)
.1.50 21 (33.3)
1.01–1.49 32 (50.8)
1.00 2 (3.2)
0.50–0.99 8 (12.7)
Total 63 (100.0)
doi:10.1371/journal.pone.0025130.t001
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of maternal anti-HBs was small (6 infants), follow-up period was
relatively short (one and half years), and the drop out rate was high
in the prospective cohort (Figure 1A), we considered that data
from larger cohort of subjects with longer follow-up period would
validate the results of the prospective study. Thus, we further
compared the anti-HBs levels in more vaccinated children born to
mothers who had high ($1000 mIU/ml) and moderate to low
(999–10 mIU/ml) anti-HBs or who were absence or almost
absence of anti-HBs (0–9.9 mIU/ml) during the pregnancy in a
retrospective survey. In the three subgroups, the mothers’ ages at
delivery were similar and positive rates of anti-HBc were
comparable (Table 3). Table 3 also shows that at around five
and half years after completion of the vaccination, the positive
rates of anti-HBs in children in these three subgroups were 72.7%,
69.2%, and 63.9% (x
2=1.505, P=0.521) respectively, and the
Figure 3. Anti-HBs IgG subclasses in paired mother-infant sera. 1, 2, 3, and 4 under the X axial indicate the subclasses IgG1, G2, G3, and G4,
respectively. Sera 018 and 020 were from mothers recovered from natural HBV infection, while sera 141 and 166 were from vaccinated mothers. The
data from 4 paired sera were used to represent anti-HBs IgG subclasses distribution in 20 paired mother/infant sera.
doi:10.1371/journal.pone.0025130.g003
Figure 4. Neutralization of HBsAg by paired mother-infant sera. An HBsAg positive serum from a hepatitis B patient was preincubated with
each of paired sera, and the unneutralized HBsAg was detected with enzyme immunoassay. The inhibition (%) was calculated by the following
formula: ([OD450 of HBsAg preincubated with anti-HBs negative serum2OD450 of HBsAg preincubated with anti-HBs]/OD450 of HBsAg
preincubated with anti-HBs negative serum)6100. Anti-HBs titers in mother serum samples 1–21 were 6613, 2644, 992, 944, 611, 565, 492, 369, 352,
318, 273, 244, 149, 148, 116, 73, 44, 36, 29, 18, and 16 mIU/ml, respectively; those in cord serum samples 1–21 were 9663, 2870, 1568, 1106, 798, 766,
616, 348, 590, 525, 255, 271, 194, 147, 291, 67, 57, 103, 31, 22, and 20 mIU/ml, respectively.
doi:10.1371/journal.pone.0025130.g004
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and 31.7 mIU/ml respectively (Kruskal-Wallis rank-sum test,
x
2=0.630, P=0.726).
Discussion
Our study confirms that anti-HBs in pregnant women may
efficiently transfer into their fetuses and the maternal anti-HBs in
the majority of newborns is higher than that in their mothers.
Furthermore, our findings demonstrate that the maternal anti-
HBs, even at high concentrations, in infants does not inhibit the
long-term immunogenicity of hepatitis B vaccine.
Placental transfer of IgG is an active process and requires the
binding of maternal IgG and neonatal Fc receptors in the placenta
[19]. As a result, the maternal antibodies in full-term newborns are
usually higher than those in their mothers [18]. In accordance
with this, we found that anti-HBs in most cord sera exceeded the
maternal levels (Table 1 and Figure 2). This may be attributed to
the predominance of anti-HBs IgG1 subclass (Figure 3), since
IgG1 is the most efficiently transferred immunoglobulin subclass
[18]. We also found that anti-HBs, induced either by natural
infection or by vaccination, was IgG1 predominance, which is in
agreement with the previous findings [15]. Therefore, as expected,
anti-HBs positive pregnant women, regardless of how the antibody
is induced, can efficiently transfer anti-HBs to their infants. In
contrast to our findings, in 60 pregnant Nigerians, transplacental
transfer of anti-HBs occurred only in 59% of the infants [20]. At
the moment, it is difficult to explain the difference. The transfer of
IgG antibody against measles virus from mothers to their infants in
Nigeria is also less efficient compared with that in German women
[21]. Thus, other coincident factors may also influence the
antibody transplacental transfer in Nigerians.
In this study, we compared the long-term immunogenicity of
hepatitis B vaccine in the retrospective group children based on
their mothers’ anti-HBs levels during pregnancy (Table 3), rather
than based on the anti-HBs levels in the children immediate after
birth. However, since the mothers’ anti-HBs level was well
correlated with that in the infants (Figure 2), the comparability of
anti-HBs positive rates and of GMC levels among the different
children subgroups (Table 3) was unlikely caused by the grouping.
Furthermore, the prospective survey showed that, one and half
years after three doses vaccine, the positive rate and GMC level of
anti-HBs were each similar to those in children with or without
maternal anti-HBs respectively (Table 2). Additionally, we found
only one natural booster, which was excluded in the analysis,
among children in the retrospective group and did not find any
natural booster in the prospective group, indicating that anti-HBs
in all children is the result of the vaccination. Therefore, the data
Table 2. Anti-HBs titers in children after vaccination with three hepatitis B vaccine doses.
Anti-HBs in cord serum (mIU/ml) Statistical analysis
$10 (n=32) 0 (n=32) Method P
Mothers’ age at delivery (year) 26.8762.54 27.0362.56 t-test, t=0.249 0.804
Gestational age (week) 39.2161.08 39.4761.33 t-test, t=0.750 0.457
Birth weight (g) 3423.166459.37 3360.486343.86 t-test, t=0.550 0.585
Male/Female 17/15 14/18 x
2 test, x
2=0.563 0.453
Delivery modes x
2 test, x
2=0.075 0.784
Cesarean section 9 10
Spontaneous labor 23 22
Children’s age 2.1660.08 2.1760.06 t-test, t=0.914 0.364
Anti-HBs+ No. (%) 29 (90.6) 28 (87.5) x
2 test, x
2=0.161 0.688
Anti-HBs (mIU/ml)
a 74.5 (6.1–884.0) 73.5 (3.1–930.2) Mann-Whitney U test, Z=20.329 0.742
aAnti-HBs level was expressed in geometric mean concentration followed by minimum and maximum values in parenthesis.
doi:10.1371/journal.pone.0025130.t002
Table 3. Long-term immune response after vaccination against hepatitis B in children born to mothers with various anti-HBs
levels.
Anti-HBs in mothers during pregnancy (mIU/ml) Statistical analysis
$1000 (n=88) 10–999 (n=94) ,10 (n=61) Method P
Maternal age 25.2263.53 24.8263.95 25.7763.23 One-way ANOVA test, F=0.752 0.282
Children’s age 6.1460.49 6.0460.57 5.8360.67 One-way ANOVA test, F=5.071 0.007
Male/Femal 50/38 51/43 37/24 x
2 test, x
2=0.618 0.734
Anti-HBc+ No. (%) 10 (11.36) 11 (11.70) 2 (3.28) x
2 test, x
2=3.644 0.162
Anti-HBs+ No. (%) 64 (72.73) 65 (69.15) 39 (63.93) x
2 test, x
2=1.305 0.521
Anti-HBs (mIU/ml)
a 38.90 (0–15000.0) 43.87 (0–5886.9) 31.65 (0–12452.9) Kruskal-Wallis rank-sum test, x
2=0.630 0.726
aAnti-HBs level was expressed in geometric mean concentration followed by minimum and maximum values in parenthesis.
doi:10.1371/journal.pone.0025130.t003
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immunogenicity of hepatitis B vaccine in infants is not inhibited by
the maternal anti-HBs.
Previously, we found that the short-term immune response to
hepatitis B vaccine in infants is impaired by high titer maternal
anti-HBs [12]. In this study, we demonstrate that the long-term
immune response to hepatitis B vaccine is not influenced by the
maternal anti-HBs, even at the high concentrations. This appears
to be somewhat unusual since the immunogenicity of many other
vaccines is to some extent blocked by the maternal antibodies [5–
11]. The mechanisms by which maternal antibodies influence
infant vaccine responses involves: (1) neutralization of live viral
vaccines, (2) inhibition of infant B cell activation by Fcc-receptor
mediated signals, (3) elimination of maternal antibody-antigen
complex through Fc-dependent phagocytosis, and (4) epitope
masking by maternal antibody, preventing antigen binding by the
B cells [6]. The hepatitis B vaccine is composed of the
recombinant HBsAg. Quantitatively, the maternal anti-HBs in
infants is in much excess of the vaccine HBsAg since one dose
vaccine usually contains only 5 or 10 mg HBsAg. Theoretically,
because the antibody in infants may bind to the HBsAg (Figure 4),
the vaccine HBsAg should be neutralized by maternal anti-HBs,
resulting in reduced immunogenicity of hepatitis B vaccine
through one or more above mechanisms. Indeed, the immune
response to two doses vaccine in infants with maternal anti-HBs is
lower than that in infants without maternal anti-HBs [12];
however, this inhibition is completely overcome by the third
immunization in infants with moderate to low maternal anti-HBs
[12], indicating that the inhibition is transient. Actually, early
reports show that high-dose hepatitis B immune globulin (anti-
HBs) may transiently impair the immune response to hepatitis B
vaccine [22,23]. Thus, the data support that priming of humoral
immune response to the vaccine HBsAg is not blocked by the
maternal anti-HBs as reported in animal experiments [24]. Such a
phenomenon also occurs in vaccination of infants with hepatitis A
vaccine in the presence of maternal antibody, in which antibody
response substantially increases following an additional vaccine
dose given six months after completion of the primary vaccination
[25]. Therefore, the inhibition of high titer maternal anti-HBs on
the immune response to the vaccine reported previously [12] may
also be transient and the current vaccination schedule against
hepatitis B may induce potent immune response in a relatively
slow manner in the presence of high titer maternal anti-HBs.
Additionally, higher-dose hepatitis B vaccine may overcome the
inhibition of maternal anti-HBs on the immune response since the
immunogenicity of three doses of 10 mg-vaccine on 0-, 1-, and 6-
month schedule was comparable in Brazilian neonates with or
without maternal anti-HBs [26].
Given the efficient transplacental transfer and higher levels of
anti-HBs in infants than in mothers, it is reasonable to assume that
infants of mothers with positive anti-HBs are immune to HBV
infection in the early life. The results that passively acquired
maternal anti-HBs in the infants efficiently bound patient-derived
HBsAg (Figure 4) support this assumption. On the other hand,
since the maternal anti-HBs in infants does not impair the long-
term immunogenicity of hepatitis B vaccine as demonstrated in the
present study, we consider that, unlike many other vaccines that
are not administrated until several months or even longer after
birth because of the interference of maternal antibodies on the
active immune response, the current hepatitis B vaccination
schedule for infants will be still effective even in the future when
most newborns are anti-HBs positives due to the transplacental
transfer of maternal anti-HBs.
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